AirSculpt (AIRS) Q2 Revenue Falls 14%

AirSculpt Technologies (NASDAQ:AIRS) reported Q2 FY2025 GAAP revenue of $44.0 million, a 13.7% year-over-year decline that missed analyst estimates, driven by a 14.1% drop in case volume and continued pressure on same-center performance. Despite these persistent demand challenges, management reaffirmed full-year FY2025 revenue and Adjusted EBITDA guidance, implying a significant sequential recovery is anticipated for the second half. While the company reduced debt and showed some sequential operational improvements, achieving its annual targets hinges on reversing current negative trends in lead conversion and existing center volume.

Analysis

AirSculpt Technologies (AIRS) reported a challenging second quarter for fiscal 2025, with GAAP revenue declining 13.7% year-over-year to $44.0 million, missing analyst estimates by 3.2%. The top-line weakness was directly attributable to a 14.1% drop in case volume, with a particularly sharp 22.0% contraction in same-center case volume, indicating persistent pressure on demand at established locations. Despite this, the company maintained its premium pricing, with revenue per case remaining flat. Profitability metrics also weakened, with adjusted EBITDA falling 15.0% to $5.8 million and diluted EPS posting a $0.01 loss against expectations of a $0.01 profit. However, management reaffirmed its full-year guidance for revenue of $160-$170 million and adjusted EBITDA of $16-$18 million, implying a required and significant operational recovery in the second half of the year. This optimism is predicated on reversing an elongated booking cycle and improving lead conversion, while the balance sheet was strengthened by a $16 million debt reduction. Potential upside from new pilots in skin tightening and consumer financing is not yet factored into guidance, while a planned CFO transition introduces a degree of management risk.

Key Decisions for Investors

• Investors should treat AirSculpt as a 'show-me' story, as the reaffirmed full-year guidance requires a significant second-half turnaround in case volume that is not supported by current trends.
• Monitor lead conversion rates and same-center volume metrics closely in the upcoming quarters, as any stabilization or improvement would be the first tangible sign of a recovery.
• Consider the new initiatives targeting GLP-1 after-effects and expanded financing as potential upside catalysts, but recognize that the ongoing CFO search introduces execution risk during this critical period.